A Phase 1 interventional study of LTX-001 once daily and Placebo in Schizophrenia, sponsored by Leal Therapeutics, Inc. Recruiting at 10 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Leal Therapeutics, Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,466 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.
Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 547th largest by planned enrollment of the 1,320 interventional ones that give a count, is one of 50 that started in 2026, is one of 196 in phase 1, reaches primary completion later than 49 of the 165 other live ones, and was the 1,450th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →148 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18–55
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,466 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 228 · Phase 2 271 · Phase 3 218 · Phase 4 193
First in 1983; this study’s year is marked. 50 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 1,320 interventional studies, 163 across the 128 observational. Of the 1,234 that completed or were terminated, 603 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
517 of 1,466 have an industry lead sponsor. The 10 most frequent:
Leal Therapeutics, Inc is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Leal Therapeutics, Inc has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
52 of the studies in Schizophrenia with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT07184619Phase 3Newron Pharmaceuticals SPAEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | 2027-03-31 |
| NCT07363577Phase 3LB Pharmaceuticals Inc.Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | 2027-06 |
Add all 52 to your calendar (.ics) → With an account.
Among the 1,466 studies in Schizophrenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute exacerbation). Additional questions it aims to answer are:
Researchers will compare different dose levels of LTX-001 to an inactive product (placebo) to see what differences there are between the two treatments.
After successfully screening for the study, participants will stay in a research unit for about five weeks and return one week later for a follow-up visit.
After providing informed consent, eligible participants will be asked to visit the study site 3 times and stay overnight for 35 nights (up to 49 nights if up to 14 days of antipsychotic washout is applicable). Procedures will include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
LTX-001
Drug: LTX-001 once daily
LTX-001
Drug: LTX-001 twice daily
LTX-001 40 mg and 60 mg administered as oral suspension
Oral suspension without LTX-001
LTX-001 30 mg and 60 mg administered as oral suspension
Safety and Tolerability - Adverse Events
Incidence and severity of treatment-emergent adverse events (TEAEs), and treatment-emergent serious adverse events (TESAEs).
Time frame: Screening through Day 42
Safety and Tolerability - Clinical Laboratory Tests
Clinical laboratory tests (including serum chemistry, hematology, urinalysis)
Time frame: Screening through Day 42
Safety and Tolerability - Electrocardiograms (ECG)
ECGs will measure heart rate (HR), QRS complex and QT, QTcF, and PR intervals
Time frame: Screening through Day 42
Safety and Tolerability - Physical and Neurological Exams
Physical and neurological exams will be performed periodically to ensure participant safety.
Time frame: Screening through Day 42
Safety and Tolerability - Suicidality
Suicidality as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
Time frame: Screening through Day 42
Safety and Tolerability - Extrapyramidal Symptoms
Extrapyramidal symptoms (EPS) as assessed by the Modified Simpson-Angus Scale (M-SAS), the Abnormal Involuntary Movement Scale (AIMS) and the Barnes Akathisia Rating scale (BARS)
Time frame: Screening through Day 42
Vital signs - blood pressure
Vital signs will be collected, including blood pressure (mm Hg)
Time frame: Screening through Day 42
Vital Signs - heart rate
Vital signs will be collected, including heart rate (beats per minute)
Time frame: Screening through Day 42
Vital Signs - respiratory rate
Vital signs will be collected, including respiratory rate (breaths per minute)
Time frame: Screening through Day 42
Vital Signs - body temperature
Vital signs will be collected, including body temperature (°C or °F)
Time frame: Screening through Day 42
Vital Signs - total body weight
Vital signs will be collected, including total body weight (kilograms)
Time frame: Screening through Day 42
Vital Signs - height
Vital signs will be collected, including height (centimeters)
Time frame: Screening through Day 42
Vital Signs - Body Mass Index (BMI)
Body Mass Index (BMI) will be calculated using the values of total body weight and height, with the formula BMI = weight in kg/(height in cm)\^2.
Time frame: Screening through Day 42
Ocular evaluation - Best Corrected Visual Acuity (BCVA)
Ocular evaluations, including Best Corrected Visual Acuity (BCVA) will be performed
Time frame: Screening through Day 42
Ocular evaluation - dilated Color Fundus Photography (CFP)
Ocular evaluations, including dilated Color Fundus Photography (CFP) will be performed
Time frame: Screening through Day 42
Ocular evaluation - Fundus Autofluorescence (FAF)
Ocular evaluations, including Fundus Autofluorescence (FAF) will be performed
Time frame: Screening through Day 42
Ocular evaluation - dilated Optical Coherence Tomography (OCT)
Ocular evaluations, including dilated Optical Coherence Tomography (OCT) of the macula and optic nerve will be performed
Time frame: Screening through Day 42
Ocular evaluation - slit lamp examination
Ocular evaluations, including slit lamp examination with measurement of intraocular pressure (IOP) will be performed
Time frame: Screening through Day 42
Pharmacokinetics of LTX-001 - Single Dose
Single-dose plasma PK parameters (Days 1 and 8) will be measured
Time frame: Days 1 and 8
Pharmacokinetics of LTX-001 - Multiple Dose
Multiple-dose plasma PK parameters (Day 35) will be measured.
Time frame: Days 8 and 35
Efficacy of LTX-001 - PANSS
Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score and subscale scores
Time frame: Screening through Day 37
Efficacy of LTX-001 - Marder factors of PANSS
Change from baseline in the Marder factors of PANSS.
Time frame: Screening through Day 37
Efficacy of LTX-001 - BACS
Change from baseline in the Brief Assessment of Cognition in Schizophrenia (BACS)
Time frame: Screening through Day 37
Efficacy of LTX-001 - CGI-S
Change from baseline in Clinical Global Impression Scale-Severity (CGI-S) score
Time frame: Screening through Day 37
Pharmacodynamics of LTX-001 - plasma glutamate and glutamine
Change from baseline in plasma glutamine (Gln) and glutamate (Glu) concentrations and Gln/Glu ratio. In addition, using glutamine change from baseline data, the individual AUEC0-4, AUEC0-12 and AUEC0-24 will be presented for each patient, by treatment group on Days 1, 8, and 35
Time frame: Day 1 through Day 36
Efficacy of LTX-001 - Quantitative electroencephalography (qEEG)
Change from baseline in resting-state qEEG parameters (alpha, beta, gamma, delta, and theta) on Days -1, 3, and 35.
Time frame: Day -1, Day 3 and Day 35
Pharmacodynamics of LTX-001 - Metabolite Profiling
Metabolite profiling and identification in pooled plasma samples of selected days from LTX-001 once and twice daily groups
Time frame: Day 1 through Day 36
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Mar 2027, 7 months after the start.
Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 7 months is below that.
Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leal Therapeutics, Inc